APOL1-mediated Proteinuric Kidney Disease
APOL1-mediated Proteinuric Kidney Disease (AMKD) is a rare genetic condition that affects kidney function, leading to protein in the urine and potentially resulting in kidney damage over time.
Kidney Disease: VX-147 Study for APOL1 Variants
We are testing the safety and effectiveness of VX-147 in adults and children with APOL1-mediated proteinuric kidney disease. The study aims to see if this treatment can improve kidney function and reduce related health risks.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you between 12 and 65 years old?
- Do you have diabetes (sugar problems)?
- Are you currently pregnant or breastfeeding?
- Are you taking blood pressure medications like Lisinopril, Losartan, or similar?
- Have you had any major heart problems or conditions?
What experimental substances are being tested?
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Vx-147
Inaxaplin
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
UZ Leuven
/
Heverlee, Belgium
Cliniques Universitaires Saint-Luc
Nephrology
Sint-Stevens-Woluwe, Belgium
Assistance Publique Hopitaux De Paris
Nephrology
Bagnolet, France
Sponsor: Vertex Pharmaceuticals Inc.
Last updated: Nov 26, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.